FCER1A and asthma: Taking these data together (Fig 1, Fig 2, Fig 3), we concluded that omalizumab treatment results in decreased FcεRI expression as well as decreased expression of CCR7, HLA-DR, and costimulatory molecules on both blood mDC and pDCs of asthma patients.